ACM
SUPN icon

Absolute Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Absolute Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15
Closed -$499 – 440
2022
Q3 		$499 Buy
+15
New +$488 ﹤0.01% 464
2022
Q1 		– Sell
-15
Closed -$437 – 428
2021
Q4 		$437 Buy
+15
New +$455 ﹤0.01% 508

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Absolute Capital Management's SUPN Position: Q4 2022 in Review

Absolute Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2022, closing a stake of 15 shares — an estimated $499 sold.

Absolute Capital Management first reported a position in SUPN in Q4 2021 and held it in 2 quarters. The position peaked at $499 in Q3 2022. 263 funds tracked by Wall St. Rank hold SUPN as of Q4 2022.

  • Absolute Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Absolute Capital Management sold 15 Supernus Pharmaceuticals shares in Q4 2022, an estimated $499.
  • Absolute Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Absolute Capital Management's Supernus Pharmaceuticals position peaked at $499 in Q3 2022.
  • 263 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2022.

Based on Absolute Capital Management's 13F filing for Q4 2022, filed 1 Feb 2023.